Israeli Medigus recieves first purchase order for muse in Italy
25 January, 2017
The order purchase order has been made by Italian INNOVAMEDICA. Medigus is in the process of obtaining regulatory clearance in China
Medigus, a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, today announced that it received the first purchase order (PO) for the MUSE system in Italy from INNOVAMEDICA S.p.A, a privately-owned distributor of minimally invasive medical devices, in accordance with their existing distribution agreement.
“Medigus’ partnership with INNOVAMEDICA will expand the commercial availability of MUSE to patients in Italy who are seeking a minimally invasive treatment option for GERD,” said Chris Rowland, CEO of Medigus. “We are pleased to offer another key market advanced technologies that enhance patient care and outcomes.”
Under terms of the four-year agreement which took effect January 1st 2017, INNOVAMEDICA S.p.A. will be required to purchase at least EUR 1M of Medigus Ultrasonic Surgical Endostapler (MUSE™) equipment over the course of the agreement.
The MUSE system is a single-use flexible transoral stapler that merges the latest advancements in microvisual, ultrasonic and surgical stapling. The device comes equipped with an ultrasonic sight and range finder and a micro ScoutCam™ CMOS camera, which enables a single physician to perform an incisionless transoral fundoplication — the procedure intended to treat the anatomical cause of gastroesophageal reflux disease (GERD).
Medigus is a medical device company specializing in developing minimally invasive endosurgical tools and highly innovative imaging solutions. Medigus are developer of the MUSE system, an FDA cleared and CE marked endoscopic device to perform Transoral Fundoplication (TF) for the treatment of GERD (gastroesophageal reflux disease), one of the most common chronic conditions in the world. MUSE is gaining adoption in key markets around the world — it is available in world-leading healthcare institutions in the U.S., Europe and Israel. Medigus is also in the process of obtaining regulatory clearance in China. Medigus is traded on the Nasdaq Capital Market and the TASE (Tel-Aviv Stock Exchange).